Immuneel to offer affordable cell and gene therapy for cancer patients in India

In this video, Arun Anand, COO, Immuneel Therapeutics and Dr Bruce Levine, of the University of Pennsylvania Perelman School of Medicine and member of Immuneel Therapeutics’ Scientific Advisory Board, explain to Viveka Roychowdhury how CAR-T cell therapy empowers patients to use their own immune cells as “drug factories”

With promising early results from the IMAGINE study on their first product, chimeric antigen receptor T (CAR-T) cell therapy Varnimcabtagene, Bengaluru-based Immuneel Therapeutics awaits approval in India.

A clinical stage start-up company in the cell & gene therapies & personalized immunotherapy, Immuneel Therapeutics was set up to provide affordable and transformational cell-based immunotherapies for cancer patients in India and the world.

With renowned co-founders like Kiran Mazumdar Shaw, board director & co-founder, executive chairperson, Biocon and Dr Siddhartha Mukherjee, cancer physician, Columbia University; scientific co-founder, Vor Biopharma and Dr Kush M Parmar, managing partner, 5AM Ventures, Immuneel Therapeutics has an enviable scientific advisory board.

In this video, Arun Anand, COO, Immuneel Therapeutics, and Dr Bruce Levine, of the University of Pennsylvania Perelman School of Medicine and member of Immuneel Therapeutics’ Scientific Advisory Board, explain to Viveka Roychowdhury how CAR-T cell therapy empowers patients to use their own immune cells as “drug factories.”

They also spell out Immuneel Therapeutics’ strategy to offer such therapies at one-third or one- fourth US costs by creating a state-of-art facility, development laboratories and cGMP-compliant manufacturing suites, and tying up with scientific and clinical partners. They also touch on new promising research exploring the use of CAR-T cell therapy beyond cancer, in autoimmune diseases like Lupus, etc.